Delivery Order SPE2DB22D2211-SPE2DB25FRYEF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $20,469.02 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order is scheduled for completion by September 18, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,372.94 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes. The contract, classified as firm fixed price with no set-aside designation, was awarded on October 22, 2025, with an ultimate completion date of October 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $3,696.56, for Boostrix TDAP vaccine in 0.5mL syringe format. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of July 18, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Performance...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,342.46 for Boostrix TDAP vaccine in 0.5mL syringe format on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order valued at $16,232.10 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by June 5, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $58,200.38 for Boostrix TDAP vaccine in 0.5 mL syringe format, with an ultimate completion date of October 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal immunization requirements...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the nation's leading pharmaceutical distributor, for the supply of Boostrix TDAP vaccine in 0.5ml syringes. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,318.30 with an ultimate completion date of September 22, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,435.48 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in syringe format (0.5mL). This non-set-aside contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a firm fixed-price delivery order. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and a key distribution hub for the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $71,577.02 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the DLA. The place of performance is listed as Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $133,843.21 on August 12, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. The contract utilizes a firm fixed-price structure with no set-aside designation, indicating competitive award. Performance will be conducted at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order is executed under...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FRYEFDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,816.22 for Boostrix TDAP vaccine in 0.5ML syringe format, with an ultimate completion date of June 2, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order falls within AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company's extensive federal contract portfolio demonstrates its capability to supply a wide range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This TDAP vaccine delivery order represents a routine fulfillment under the company's broader pharmaceutical prime vendor agreement, which enables flexible supply of medications, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 5/30/25 |